Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Culture-confirmed invasive Candida infection~Exclusion Criteria:~* Candida disease limited to the oropharynx, esophagus, or other mucosal or superficial skin surfaces~* Positive culture for Candida only from sputum, broncho-alveolar lavage, catheter tip, or previously placed indwelling non-vascular catheters or drains~* Prosthetic device as the suspected site of Candida infection~* Active co-infection with a non-Candida fungal organism~* Received \>48 hours of systemic antifungal treatment since the positive Candida index culture was collected as therapy for the present episode of invasive candidiasis~* Failed prior systemic antifungal therapy for the present episode of invasive candidiasis~* Diagnosis of acute hepatitis or cirrhosis~* Scheduled or anticipated to receive rifampin or other systemic antifungal therapy while on study therapy~* History (including participant's mother) of allergy, hypersensitivity, or any serious reaction to caspofungin or other member of the echinocandin class, or to amphotericin B deoxycholate or other member of the polyene class~* Severe congenital disorder known to lower immune response

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Caspofungin (Type: EXPERIMENTAL): Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
- Amphotericin B Deoxycholate (Type: ACTIVE_COMPARATOR): Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).